Endometrial cysteine-rich secretory protein 3 is inhibited by human chorionic gonadotrophin, and is increased in the decidua of tubal ectopic pregnancy

Citation for published version:

Digital Object Identifier (DOI):
10.1093/molehr/gap019

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Molecular Human Reproduction

Publisher Rights Statement:
Copyright © 2013 European Society of Human Reproduction and Embryology

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Endometrial cysteine-rich secretory protein 3 is inhibited by human chorionic gonadotrophin, and is increased in the decidua of tubal ectopic pregnancy

A.W. Horne1,5, W.C. Duncan1, A.E. King1, S. Burgess2, P.C. Lourenco1, P. Cornes1, P. Ghazal2, A.R. Williams3, L. Udby4, and H.O.D. Critchley1

1Division of Reproductive and Developmental Sciences, The University of Edinburgh, Edinburgh, UK 2Division of Pathway Medicine, The University of Edinburgh, Edinburgh, UK 3Division of Pathology, The University of Edinburgh, Edinburgh, UK 4Granulocyte Research Laboratory, Copenhagen University Hospital, Rigshospitalet, Denmark 5Correspondence address. Division of Reproductive and Developmental Sciences, The University of Edinburgh, Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SB, UK. Tel: +44-13-12-42-26-94; Fax: +44-13-12-42-26-86; E-mail: andrew.horne@ed.ac.uk

ABSTRACT: Ectopic pregnancy (EP) remains a considerable cause of morbidity and occasional mortality. Currently, there is no reliable test to differentiate ectopic from intrauterine gestation. We have previously used array technology to demonstrate that differences in gene expression in decidualized endometrium from women with ectopic and intrauterine gestations could be used to identify candidate diagnostic biomarkers for EP. The aim of this study was to further investigate the decidual gene with the highest fold increase in EP, cysteine-rich secretory protein-3 (CRISP-3). Decidualized endometrium from gestation-matched women undergoing surgical termination of pregnancy (n = 8), evacuation of uterus for miscarriage (n = 6) and surgery for EP (n = 11) was subjected to quantitative RT–PCR, morphological assessment, immunohistochemistry and western blot analysis. Sera were analysed for progesterone and human chorionic gonadotrophin (hCG) levels. Immortalized endometrial epithelial cells were cultured with physiological concentrations of hCG. CRISP-3 mRNA and protein expression were greater in endometrium from ectopic when compared with intrauterine pregnancies (P < 0.05). CRISP-3 protein was localized to epithelium and granulocytes of endometrium. CRISP-3 serum concentrations were not different in women with ectopic compared with intrauterine pregnancies. CRISP-3 expression in endometrium was not related to the degree of decidualization or to serum progesterone levels. Endometrial CRISP-3 expression was inversely proportional to serum hCG concentrations (P < 0.001). Stimulation of endometrial epithelial cells with hCG in vitro caused a reduction in CRISP-3 expression (P < 0.01). The measurement of CRISP-3 in endometrium could provide an additional tool in the diagnosis of failing early pregnancy of unknown location. The absence of a local reduction in expression of CRISP-3 in decidualized endometrium of women with EP may be due to reduced exposure to hCG due to the ectopic location of the trophoblast.

Key words: ectopic pregnancy / decidualized endometrium / CRISP-3 / hCG

Introduction

Tubal ectopic pregnancy remains a common cause of morbidity and mortality (Farquhar, 2005). In the UK, between 2003 and 2005, early pregnancy bleeding was the third most common cause of maternal death, and more than 60% of these cases were due to ruptured tubal ectopic pregnancies (Saving Mother’s Lives, 2008). In the USA, ruptured tubal ectopic pregnancy remains the most common cause of pregnancy-related death in the first trimester (Mukul and Teal, 2007). Unfortunately, our knowledge of the complex molecular and cellular interactions that contribute to tubal implantation is limited. Furthermore, despite the use of serial serum beta-human chorionic gonadotrophin (hCG) concentrations and transvaginal...
ultrasonography, diagnosis remains difficult (ASRM, 2006). Indeed, tubal ectopic pregnancy is frequently not diagnosed, or misdiagnosed, at the initial visit (Duncan et al., 1995; Robson and O’Shea, 1996).

The development of a biomarker that can differentiate a tubal ectopic implantation from an intrauterine implantation is therefore important. In the pre-genomic era, a one-by-one scientific approach has been unsuccessful in revealing markers that could be used as a test for tubal ectopic pregnancy (Birkhahn et al., 2001; Wegner and Mershon, 2001; Develioglu et al., 2002; Florio et al., 2007). However, we have recently shown that high-density oligonucleotide microarray analysis is helpful in identifying novel genes that are altered during tubal implantation (Horne et al., 2008). Using this technology, we demonstrated that a secreted product, Activin B, from the decidualized endometrium was a candidate biomarker for tubal ectopic pregnancy (Horne et al., 2008).

During that study, the gene with the highest fold increase in the decidualized endometrium of ectopic pregnancy, when compared with that of intrauterine pregnancy (FC = 13.10), was cysteine-rich secretory protein 3 (CRISP-3). CRISP-3, which is also known as specific granule protein of 28 kDa (SGP28), belongs to a family of CRISPs characterized by their size (220–230 amino acids), their secretory properties and a content of 16 highly conserved cysteine residues, which form intra-molecular disulphide bond (Kjeldsen et al., 1996; Gibbs and O’Bryan, 2007). In humans, CRISP-3 mRNA has been detected at high concentrations in the salivary glands, pancreas and prostate, and at lower levels in the epididymis, ovary, thymus and colon (Kratzschmar et al., 1996). Furthermore, CRISP-3 is secreted and can be detected in human tissue fluids such as saliva, sweat, blood and seminal plasma making it an ideal candidate biomarker for pathophysiological conditions, such as ectopic pregnancy (Udby et al., 2002a; Bjartell et al., 2006).

We hypothesized that, since CRISP-3 is secreted, if decidual CRISP-3 expression is higher in ectopic pregnancy, this could form the basis of a novel test for tubal implantation. This study aimed to further investigate CRISP-3 expression, localization and regulation in the decidualized endometrium of women with tubal ectopic pregnancy. In addition we aimed to use such analyses to inform us about the molecular regulation of endometrial function during normal early pregnancy. Herein we report the identification, expression, localization, underlying biological regulation and serum concentrations of CRISP-3 in gestation-matched women with tubal and intrauterine implantation.

Materials and Methods

Tissue collection

Ethical approval for this study was obtained from Lothian Research Ethics Committee and informed written consent was obtained from all patients before sample collection. First trimester decidualized endometrium was obtained from gestation-matched women (age 18–45 years) undergoing surgical termination of pregnancy (TOP, n = 8, Group 1, mean gestation 58.7 days), surgical management of embryonic missed miscarriage (n = 6, Group 2, mean gestation 57.7 days) and surgical management of tubal pregnancy (n = 11, Group 3, mean gestation 58.1 days). None of the women undergoing surgical management of tubal ectopic pregnancy presented acutely with hemodynamic shock, and all required serial serum hCG and ultrasound monitoring prior to diagnosis. The decidualized endometrium and trophoblast were obtained by suction curettage from Groups 1 and 2. The decidualized endometrium was obtained by suction endometrial biopsy (Pipelle™, Eurosurgical Ltd, Cranleigh, UK) from Group 3. The decidualized endometrium was isolated from the trophoblast macroscopically and was (i) immersed in RNAlater™ (Ambion, TX, USA) at 4°C overnight then flash frozen at −70°C; and (ii) fixed in 10% neutral buffered formalin overnight at 4°C, stored in 70% ethanol and wax embedded for staining with haematoxylin and eosin and immunohistochemistry. The presence of trophoblast was ruled out morphologically and by using immunohistochemical staining for cytokeratin as described previously (Ball et al., 2006).

RNA extraction

Total RNA was extracted from the decidualized endometrium and cell culture experiments as detailed in the manufacturers’ protocol (Qiagen, West Sussex, UK). The concentration and quality of the extracted RNA was assessed using an Agilent bioanalyzer and quantified using an ND-1000 spectrophotometer (Nanodrop technologies, DE, USA). All samples were standardized for quality control and assigned an RNA integrity number (RIN). RNA samples were considered to be of good quality when a mean RIN value of 7.5 was obtained (Schroeder et al., 2006).

Microarray analysis

The conduct and robust standardization and assessment of the microarray study that informed this study have been reported previously (Horne et al., 2008). The microarray analysis involved 25 samples. Gene lists were created using a fold change threshold of ≥2 and a corrected P-value of <0.05, and CRISP-3 had the highest fold change in ectopic pregnancy (13.10).

Quantitative RT–PCR

After DNase treatment, using RQ1 DNase (Promega, Southampton, UK) the RNA was reverse transcribed into cDNA using random hexamers (Applied Biosystems, Foster City, CA, USA). Taqman Quantitative RT–PCR was then used to measure gene levels in all 25 samples. Applied Biosystems pre-validated ‘assay-on-demand’ specific primers and probes were used for analysis of tissue samples. cDNA from cell culture experiments was assayed for CRISP-3 using validated primers and the Universal Probe Library (www.universalprobelibrary.com, Roche Diagnostics, Germany). All sample reactions were performed in triplicate. Using the 2-ΔΔCt method, CRISP-3 mRNA expression results were normalized against ribosomal 18S internal control (Applied Biosystems) and expressed as the fold-change when compared with controls (TOP sample group or untreated control).

Immunohistochemistry

Briefly, immunolocalization of CRISP-3 was carried out using an anti-human CRISP-3 monoclonal antibody in all 25 samples (MAB23971, R&D Systems, Minneapolis, USA). In order to perform the experiment in a controlled and easily repeatable manner, the Bond-X automated immunostaining machine (Vision Biosystems, Newcastle, UK) was utilized. Paraffin sections of uterine decidua (5 μm) were cut, dewaxed, rehydrated and subjected to antigen retrieval in Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA, USA) for 15 min in the microwave before being placed on the Bond-X machine. This method on the Bond-X automated machine utilizes a specific polymer high-contrast program (Bond Refine Polymer detection kit). Slides were peroxidase blocked for 5 min, incubated for 3 h with the primary antibody at 2.5 μg/ml in the Bond diluent supplied and then incubated with the post-primary reagent for 8 min. To confirm antibody specificity, control sections were incubated with diluent alone or with non-specific mouse immunoglobulins, diluted...
to the same concentration as primary antibody in supplied diluent. Protsate was used as a positive control (Udby et al., 2005). Sections were then incubated with the polymer reagent for 8 min to increase sensitivity of detection prior to DAB detection for 10 min. Sections were counter-stained in haematoxylin for 5 min. Slides were then removed from the machine and dehydrated and mounted using Pertex. The localization of CRISP-3 was assessed by two independent observers blinded to tissue identity, and it was consistent throughout all samples.

Western blot analysis
Total protein from all 25 decidualized endometrial biopsies was prepared by homogenization (TissueLyser, Qiagen, UK) of RNALater™ treated frozen tissue in buffer (% Triton X, 0.1% SDS, 0.5% deoxycholic acid, 0.15 M NaCl, 0.02 M Tris) containing a protease inhibitor cocktail (Complete, Roche Diagnostics, Mannheim, Germany). The proteins in the supernatants were measured by the method of Bradford (Schleicher and Wieland, 1978) adapted for use on a Cobas Fara Centrifugal Analyser (Roche Diagnostics). Protein samples (20 µg) were run on 4–12% Novex bis-tris gels in NuPAGE MOPS SDS buffer (Invitrogen, CA, USA). Proteins were transferred onto a PVDF membrane (Immobilon-P, Millipore, MA, USA) in Tris/glycine/methanol. After blocking in 5% skimmed milk/PBS for 1 h, the membrane was washed with 0.5% BSA/PBS. The membrane was incubated overnight at 4°C with polyclonal rabbit anti-CRISP-3 IgG (1 µg/ml) in 0.5% BSA/PBS (or CRISP-3 monoclonal antibody, R&D Systems, Minneapolis, USA). Immunoblotting for β-actin (Abcam, Cambridge, UK) was used as a comparative control between the samples. After washes in 0.5% BSA/PBS, incubation with anti-rabbit HRP antibody (A1949, Sigma, Dorset, UK) followed for 1 h at room temperature. The membrane was washed as before, incubated with HRP substrate solution (Immobilon Western, Millipore, MA, USA) for 5 min and exposed to Amersham Hyperfilm ECL (GE Healthcare, Buckinghamshire, UK). Images were also captured digitally using the VersaDoc Imaging System (BioRad, CA, USA) and band density was assessed and corrected for β-actin density on a Photoshop CS2 platform (Adobe, CA, USA).

Statistical analysis
All data were assessed for normality of distribution using a computer programme (Prism 4; Graphpad Software, CA, USA). Where the data were normally distributed, three groups were analysed by ANOVA with Bonferroni pairwise comparisons. Two groups were analysed using a t-test. Where the data were not normally distributed, Kruskal–Wallis testing with Dunn’s pairwise comparisons was used to compare three groups. Chi-squared test was used to compare proportions, and Spearman (non-parametric) or Pearson (parametric) coefficients were used to assess linear correlations. The statistical test used is given in the text and figure legend and significance was at the P < 0.05 level.

Results
CRISP-3 mRNA is increased in decidualized endometrium from tubal ectopic compared with intrauterine pregnancies
A previously published comparison of gene expression in the decidualized endometrium from women with intrauterine (n = 14) and tubal pregnancies (n = 11) revealed that of the 669 genes that were differentially expressed (FC > ± 2, P < 0.05) (Horne et al., 2008), CRISP-3 was up-regulated in the women with tubal ectopic pregnancies with the highest fold increase (FC = 13.10). Quantitative RT–PCR confirmed its increased expression in the decidualized endometrium from tubal pregnancies when compared with both miscarriage (P < 0.01) and TOP (P < 0.01) groups (Fig. 1).

CRISP-3 protein is immunolocalized to the epithelium and granulocytes in decidualized endometrium
In order to further investigate CRISP-3 in the decidualized endometrium, it was localized using immunohistochemistry. Specific immuno-staining for CRISP-3 could be detected in the glandular epithelium, secreted within the glands (Fig. 2A–C) and in the...
CRISP-3 protein is increased in decidualized endometrium from tubal ectopic compared with intrauterine pregnancies

Western blot analysis of decidual biopsies from patients with tubal ectopic (n = 11), miscarriages (n = 6) and viable pregnancies (n = 8) revealed bands of 29 and 27 kDa corresponding to N-glycosylated and non-glycosylated CRISP-3 (Udby et al., 2005) (Fig. 3). Glycosylated CRISP-3 was increased in the decidualized endometrium from tubal ectopic pregnancy when compared with that from miscarriages and viable pregnancies (Fig. 3).

CRISP-3 serum concentrations are similar in women with tubal ectopic compared with intrauterine pregnancies

As CRISP-3 is a secreted protein that is increased in the decidualized endometrium of ectopic pregnancy, serum concentrations were analysed to determine if these mirrored endometrial expression. Serum samples from patients with tubal ectopic pregnancies (n = 11), miscarriages (n = 6) and viable pregnancies (n = 8) were assayed for CRISP-3 protein. There were no significant differences in measured CRISP-3 concentrations (Fig. 4).
CRISP-3 expression is not related to the morphology of the decidualized endometrium

As the decidualization of endometrium is different in the tubal ectopic, miscarriage and viable pregnancy groups (Horne et al., 2008), the relationship of CRISP-3 expression to decidual morphology was investigated. As previously demonstrated (Horne et al., 2008), in decidualized endometrium from women with tubal ectopic pregnancies, the glandular compartment \( (P < 0.05) \) showed a lesser degree of secretory transformation and the stromal compartment \( (P < 0.05) \) showed less decidualization when compared with intrauterine pregnancies (data not shown). When the samples were stratified based on the overall degree of morphological decidualization, there was however no clear correlation with CRISP-3 mRNA expression (Fig. 5A) or serum concentrations (data not shown).

CRISP-3 mRNA expression is not related to serum progesterone, but is inversely proportional to serum hCG concentrations

As the degree of decidualization did not explain the observed differences in CRISP-3, its expression was investigated in relation to serum progesterone and hCG concentrations (Fig. 5B and C, respectively). There was no clear correlation between CRISP-3 mRNA expression and serum progesterone \( (P > 0.05; \text{Fig. 5B}) \). However, when the samples were analysed according to serum hCG, there was a marked correlation with CRISP-3. Expression of CRISP-3 mRNA in decidualized endometrium was inversely proportional to serum hCG \( (P = 0.0006; r = -0.64; \text{Fig. 5C}) \).

hCG regulates CRISP-3 mRNA expression in endometrial epithelial cells in vitro

As endometrial epithelial CRISP-3 mRNA expression was inversely related to serum hCG concentrations in vivo, we hypothesized that hCG could inhibit CRISP-3 epithelial expression. We therefore assessed the effect of hCG treatment on CRISP-3 expression in endometrial epithelial cells in vitro. At both 6 and 24 h, hCG treatment of the cell line was associated with a dose-dependent decrease in endometrial epithelial CRISP-3 mRNA expression \( (P < 0.01; \text{Fig. 6}) \).

Discussion

This study demonstrates a clear difference between the decidualized endometrium of tubal ectopic and intrauterine pregnancies of similar gestational ages, that may be reflected by an alteration in endometrial secretory function. We have shown that decidual expression of CRISP-3 is increased in tubal ectopic pregnancies when compared with intrauterine pregnancies. In addition, the expression of CRISP-3 mRNA in the decidualized endometrium appears to be negatively regulated by hCG. These data suggest that during early intrauterine pregnancy, endometrial CRISP-3 expression may be inhibited by hCG and that this does not occur to the same degree in tubal ectopic pregnancy.

Disappointingly, although we demonstrated increased CRISP-3 mRNA and protein expression in the decidualized endometrium of women with tubal ectopic pregnancies, we were unable to replicate this finding in matched serum samples. As other organs and tissue types, such as the salivary glands and pancreas, can contribute to the blood level of CRISP-3, the total endometrial impact may be low. The determination of CRISP-3 concentration in serial samples across the menstrual cycle and after hysterectomy may address this issue in more detail. At present, this study was not able to demonstrate a role for CRISP-3 as a serum biomarker. However, it may be that further assay refinements would increase the sensitivity and
remains possible that biomarker in the future.

Horne instances. For example, the rapid measurement of with ‘pathogenesis-related proteins’, involved in plant anti-microbial

secretion location requires further study.

of outpatient endometrial sampling in the rapid assessment of preg-

nancy. The first strategy was to examine whether it changed during

expression correlated with local and systemic variables in early preg-

sions in the endometrial expression of genes that regulate the

implantation.

expression is unclear. Further work therefore needs to be done to investigate CRISP-3 expression in the endome-

trium and its role across the menstrual cycle and at the time of

implantation.

Whatever the role of CRISP-3 at the time of implantation, it is clear

that endometrial expression in early gestation is higher in tubal ectopic

pregnancy. The most obvious difference in the decidualized endome-

trium from the tubal pregnancy compared with the intrauterine groups

is the absence of a local trophoblast. The trophoblast has important

effects on the endometrium. Indeed, the effect of pregnancy on the

endometrium using the model of ectopic pregnancy has been

studied in another microarray study, demonstrating effects on the

complement and coagulation cascade, phospholipid degradation, glyco-

sphingolipid biosynthesis, retinol metabolism, antigen presentation

pathway, glycosphingolipid biosynthesis and O-glycan biosynthesis

(Savaris et al., 2008). Recent in-vitro studies, also using a functional

genomics approach, have shown that conditioned media from tropho-

blast alter the local immune environment of the uterine decidua to

facilitate embryo implantation by causing a significant induction of

pro-inflammatory cytokines and cells (Hess et al., 2007). This suggests

that differences between decidualized endometrium in ectopic and

intrauterine gestations may be the result of local trophoblast products.

In order to investigate why CRISP-3 was increased in the decidua of

ectopic pregnancies, we analysed whether the variation in CRISP-3

expression correlated with local and systemic variables in early preg-

nancy. The first strategy was to examine whether it changed during

decidualization. The endometrium of ectopic pregnancies is less decid-

ualized than that of intrauterine pregnancies (Horne et al., 2008).

Unlike Activin B, which appears to be a decidual-related marker of

ectopic pregnancy (Horne et al., 2008), CRISP-3 expression is not

related to the degree of decidualization. As progesterone concentra-

tions tend to be lower in ectopic pregnancy, we also assessed

whether progesterone concentrations were related to CRISP-3

expression and found no relationship between serum progesterone

and decidual CRISP-3 expression. This negative finding is perhaps

not surprising as progesterone receptors disappear from the endo-

metrial glands during the secretory phase (Koh et al., 1995) of the

cycle.

We found a highly significant negative correlation between decidual

CRISP-3 expression and serum hCG concentrations. During the peri-

implantation period of pregnancy in primates, hCG is the first clear

signal of the trophoblast’s presence and viability (Hearn et al.,

1988). Indeed, primate studies have shown that hCG induces altera-

tions in the endometrial expression of genes that regulate the

specificity of the assay and CRISP-3 remains a possible candidate for a

biomarker in the future.

If there are no useful differences in serum CRISP-3 concentrations, it

remains possible that CRISP-3 could function as a biomarker in other

instances. For example, the rapid measurement of CRISP-3 in a small

biopsy of the uterine decidua could provide the clinical pathologist

with an additional means of diagnosing ectopic pregnancy in any

woman with a failing early pregnancy of unknown location. The use

of outpatient endometrial sampling in the rapid assessment of preg-

nancy location requires further study.

However, the endometrium in early pregnancy does express and

secretes CCRPS-3 and the difference between intrauterine and tubal ges-
tation suggests that this expression is regulated. However, its role

within the human decidualized endometrium is not yet clear. It has

been suggested that CRISP-3 may have a role in the human innate

immune defence system. It is likely that the poorly understood

innate immune mechanisms and their involvement during implantation

have roles in facilitating successful human fertility. The role for CRISP-3

in human innate immune defence is supported by the expression of

CCRPS-3 in neutrophils and in exocrine glands, and sequence similarities

with ‘pathogenesis-related proteins’, involved in plant anti-microbial

defence (Stintzi et al., 1993; Udby et al., 2002a). Certainly in normal

early pregnancy, it appears that there is lower endometrial CRISP-3

expression. This has clear parallels with the decidual expression of

another key mediator of the innate immune system. Secretory leuco-

cyte protease inhibitor is also relatively increased in the decidualized

endometrium of women with tubal ectopic pregnancies when com-

pared with those with intrauterine implantation (Dalgetty et al.,

2008). Together, these findings suggest that the endometrium has

an innate immunity that is locally regulated during early pregnancy.

It is possible that CRISP-3 has a role in endometrial tissue remodel-

ling as it is localized to specific and gelatinase-containing granules in

human neutrophils. This suggests a matrix degradative role, as these

granules are partially exocytosed during neutrophil migration and

inflammation (Udby et al., 2002b). In addition, CRISP-3 appears to

be up-regulated in chronic pancreatitis (Friess et al., 2001), further

supporting a role for CRISP-3 in localized tissue inflammatory and

immune response. Although there are clear morphological and func-

tional changes in the endometrium across the menstrual cycle, the

ontogeny of CRISP-3 expression is unclear. Further work therefore

needs to be done to investigate CRISP-3 expression in the endome-

trium and its role across the menstrual cycle and at the time of

implantation.

Figure 6 Regulation of endometrial epithelial CRISP-3 expression

in vitro.

At both 6 and 24 h, hCG treatment (100 IU/ml) was associated with a dose

dependent decrease in endometrial CRISP-3 mRNA expression (n = 3)

(P < 0.01; ANOVA).
modulation of the immune response around the implanting trophoblast (Sherwin et al., 2007). We realize the limitations of our in-vitro experimentation with hCG and short-term culture but, together with our in-vivo observations, our findings suggest that CRISP-3 may be an endometrial gene that can be regulated by hCG during early pregnancy. It is therefore suggested that with tubal implantation, the absence of a local reduction in the expression of CRISP-3 in the decid-ualized endometrium of women with tubal ectopic pregnancy may be due to the impaired production, or local effect, of hCG from the trophoblast.

In summary, CRISP-3 is expressed in the decidualized endometrium of pregnancy and is higher in tubal ectopic pregnancy. Its inverse relationship with serum hCG concentrations and the inhibition of CRISP-3 by hCG in vitro suggests that it may be directly inhibited by the conceptus. This may have a role in the control of innate immunity during implantation.

Acknowledgements
The authors would like to thank: Sharon McPherson and Catherine Murray for patient recruitment; Ronnie Grant for manuscript preparation; and the Ectopic Pregnancy Trust for their continued support.

Funding
This work was supported by Tenovus Scotland, The Barbour Watson Trust and NHS Lothian Research and Development (A.W.H.), The Cunningham Trust (W.C.D.), the Caledonian Research Foundation (A.E.K.) and the Wellcome Trust (P.G.).

References
Sherwin JR, Sharkey AM, Cameo P, Mavrogianis PM, Catalano RD, Edassery S, Fazleabas AT. Identification of novel genes regulated by...


Submitted on November 25, 2008; resubmitted on February 25, 2009; accepted on February 27, 2009.